Pancreatic Cancer Research

ResearcherAsan Medical CenterActive in the last 2 years

Jae Ho Byun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2076-9979; OpenAlex author ID A5051148493. Sources: OpenAlex.

Their work

Papers
19 (first author 3, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
38
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 4 papers · 2022: 3 papers · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 19

  1. Differentiating large-duct pancreatic ductal adenocarcinoma from malignant intraductal papillary mucinous neoplasm: MRI characteristics and diagnostic implicat… Co-author DOI 10.1016/j.ejrad.2026.112735↗
  2. Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pancreatic Cancer. First author DOI 10.1245/s10434-024-16437-9↗
  3. ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Pancreatic Cancer. First author DOI 10.1245/s10434-024-16618-6↗
  4. Comparison of the different versions of NCCN guidelines for predicting margin-negative resection of pancreatic cancer in patients undergoing upfront surgery. Co-author DOI 10.1007/s00261-024-04299-4↗
  5. Predicting Recurrence-Free Survival After Upfront Surgery in Resectable Pancreatic Ductal Adenocarcinoma: A Preoperative Risk Score Based on CA 19-9, CT, and 1… Last author DOI 10.3348/kjr.2023.1235↗
  6. Large Duct Pancreatic Ductal Adenocarcinoma: A Morphological Variant of Pancreatic Ductal Adenocarcinoma With Distinct CT and MRI Characteristics. Last author DOI 10.3348/kjr.2023.0521↗
  7. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resectio… Co-author DOI 10.1002/jhbp.1192↗
  8. Pancreatic ductal adenocarcinoma with a predominant large duct pattern has better recurrence-free survival than conventional pancreatic ductal adenocarcinoma: … Co-author DOI 10.1016/j.humpath.2022.05.018↗
  9. Preoperative data-based deep learning model for predicting postoperative survival in pancreatic cancer patients. Co-author DOI 10.1016/j.ijsu.2022.106851↗
  10. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer. Co-author DOI 10.1007/s00330-020-07134-8↗
  11. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. First author DOI 10.1007/s00330-020-07188-8↗
  12. Meta-analysis of CT and MRI for differentiation of autoimmune pancreatitis from pancreatic adenocarcinoma. Co-author DOI 10.1007/s00330-020-07416-1↗
  13. CT in the prediction of margin-negative resection in pancreatic cancer following neoadjuvant treatment: a systematic review and meta-analysis. Co-author DOI 10.1007/s00330-020-07433-0↗
  14. Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of … Co-author DOI 10.1148/radiol.2020200281↗
  15. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. Co-author DOI 10.1177/1758835920953294↗
  16. Differentiating focal autoimmune pancreatitis and pancreatic ductal adenocarcinoma: contrast-enhanced MRI with special emphasis on the arterial phase. Co-author DOI 10.1007/s00330-019-06200-0↗
  17. Comparison of diagnostic performance between CT and MRI in differentiating non-diffuse-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-018-5565-1↗
  18. Pancreatic Cancer CT: Prediction of Resectability according to NCCN Criteria. Co-author DOI 10.1148/radiol.2018180628↗
  19. Diagnostic Strategy for Differentiating Autoimmune Pancreatitis From Pancreatic Cancer: Is an Endoscopic Retrograde Pancreatography Essential? Co-author DOI 10.1097/mpa.0b013e31823a509b↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Seung Soo Lee · 16 shared papers, 2012–2026 · strength 2.41
  2. Hyoung Jung Kim · 15 shared papers, 2018–2025 · strength 2.25
  3. Jin Hee Kim · 15 shared papers, 2012–2025 · strength 2.14
  4. Song Cheol Kim · 11 shared papers, 2018–2025 · strength 1.67
  5. Seung‐Mo Hong · 8 shared papers, 2018–2025 · strength 1.36
  6. Dae Wook Hwang · 7 shared papers, 2020–2026 · strength 1.30
  7. Kyu‐pyo Kim · 8 shared papers, 2020–2025 · strength 1.24
  8. Changhoon Yoo · 8 shared papers, 2020–2025 · strength 1.24
  9. Jong Keon Jang · 6 shared papers, 2021–2025 · strength 1.05
  10. Se Jin Choi · 5 shared papers, 2022–2025 · strength 0.96
  11. Ki Byung Song · 5 shared papers, 2018–2026 · strength 0.70
  12. Dong‐Wan Seo · 4 shared papers, 2021–2025 · strength 0.68
  13. Dong Wook Kim · 3 shared papers, 2020–2023 · strength 0.47
  14. Woohyung Lee · 3 shared papers, 2020–2024 · strength 0.43
  15. Sung Joo Kim · 2 shared papers, 2022–2023 · strength 0.36
  16. Dong Wan Seo · 2 shared papers, 2020–2025 · strength 0.32
  17. Se Jin Choi · 1 shared paper, 2026 · strength 0.28
  18. Ji Hun Kang · 2 shared papers, 2021 · strength 0.25
  19. Moon-Gyu Lee · 3 shared papers, 2012–2021 · strength 0.23
  20. Seung Baek Hong · 2 shared papers, 2018–2021 · strength 0.23
  21. Baek‐Yeol Ryoo · 2 shared papers, 2020–2021 · strength 0.22
  22. Boryeong Jeong · 1 shared paper, 2024 · strength 0.21
  23. Myung‐Hwan Kim · 3 shared papers, 2012–2020 · strength 0.20
  24. Eun Joo Park · 1 shared paper, 2024 · strength 0.20
  25. Seong Ho Park · 2 shared papers, 2012–2021 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.